In the randomized phase II DANTE trial of the Association of Medical Oncology of the German Cancer Society (AIO), atezolizumab (anti-PD-L1) plus chemotherapy was compared to the standard monochemotherapy in patients with resectable EGC. Here, CD274 is linked to cancer.